REFERENCES
- National Institutes of Health (NHLBI). The Management of Sickle Cell Disease. Bethesda, MD: National Institutes of Health; 2002. NIH publication no 02–2117.
- Adams RJ, McKie VC, Hsu L, Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med. 1998;339:5–11.
- Adams RJ, Brambilla D. Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease. N Engl J Med. 2005;353:2769–2778.
- Vichinsky E, Butensky E, Fung E, Comparison of organ dysfunction in transfused patients with SCD or beta thalassemia. Am J Hematol. 2005;80:70–74.
- Darbari DS, Kple-Faget P, Kwagyan J, Circumstances of death in adult sickle cell disease patients. Am J Hematol. 2006;81:858–863.
- Borgna-Pignatti C, Cappellini MD, De Stefano P, Survival and complications in thalassemia. Ann N Y Acad Sci. 2005;1054:40–47.
- Modell B, Khan M, Darlison M. Survival in β-thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet. 2000;355:2051–2052.
- Silliman CC, Peterson VM, Mellman DL, Iron chelation by deferoxamine in sickle cell patients with severe transfusion-induced hemosiderosis: a randomized, double-blind study of the dose-response relationship. J Lab Clin Med. 1993;122:48–54.
- Cohen AR, Martin MB. Iron chelation therapy in sickle cell disease. Semin Hematol. 2001;38(Suppl 1):69–72.
- Voskaridou E, Douskou M, Terpos E, Deferiprone as an oral iron chelator in sickle cell disease. Ann Hematol. 2005;84:434–440.
- Vichinsky E, Onyekwere O, Porter J, A randomized comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol. 2006;136:501–508.
- Rees DC, Olujohungbe AD, Parker NE, Guidelines for the management of the acute painful crisis in sickle cell disease. Br J Haematol. 2003;120:744–752.
- Ballas SK. Treatment of pain in adults with sickle cell disease. Am J Hematol. 1990;34:49–54.
- Rogers ZR, lieff S, McMurray M, Collaborative data project [C-DATA] of the comprehensive sickle cell centers program. Blood. 2006;108(11): Abstract 1200.
- Cappellini MD. Overcoming the challenge of patient compliance with iron chelation therapy. Semin Hematol. 2005;42:S19–S21.
- Treadwell M, Sung J, Murray E, Barriers to deferoxamine adherence for adults with sickle cell disease. Blood. 2004;104(11): Abstract 3760.